New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 25, 2013
06:33 EDTIMGNImmunoGen says T-DM1 marketing application under review in U.S, Europe
ImmunoGen expects to reports clinical findings for three compounds and expects to advance its fourth compound, IMGN289, into clinical testing.
News For IMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
08:29 EDTIMGNImmunoGen price target raised to $24 from $13 at Oppenheimer
Oppenheimer hiked its price target on ImmunoGen as the firm thinks that updates on its '853 drug will better frame the drug's value. The firm believes that several other positive catalysts will propel the stock higher in 2016. It keeps an Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use